Finally, we developed a proof-of-principle dual-targeting CAR against both BCMA and CD70 as a potential strategy to avoid antigen escape–mediated resistance in #HRMM (9/10)

We also evaluated epigenetic regulation of CD70 in #myeloma, using a machine learning model to predict and then test key transcriptional regulators of surface expression (8/10)

While all anti-CD70 CARs demonstrated clear efficacy against myeloma cell line xenograft models in vivo, the CD27-based CAR showed remarkable >80-fold expansion‼️ versus scFv-based CARs, suggesting a highly favorable phenotype for clinical translation (7/10)

We then used the crystal structure of CD70 bound to its natural receptor CD27 to develop a structure-guided, optimized CD27-based CAR to compare to standard “scFv” based CAR, using frameworks containing either CD28 or 4-1BB costim domains. (6/10)

Analysis of paired tumor RNA sequencing data from
‪@themmrf.bsky.social‬ CoMMpass study, cell surface #proteomics, and flow cytometry revealed CD70 was present on primary #myeloma. CD70 transcript was strongly enriched in high risk genotypes t(4;14), gain 1q, and loss 1p (5/10)

Excited to share our new manuscript, now published in Blood! BCMA #CART show impressive responses for #myeloma, but pts with high-risk cytogenetics relapse more quickly and are in urgent need of new therapies. Thread👇 (1/10) ashpublications.org/blood/articl...

Beautiful day and amazing turnout to hear keynote speaker and Nobel laureate Carolyn Bertozzi speak in San Francisco at today’s protest in defense of federal science funding #StandUpForScience2025 #StandUpForScience

So happy to see so many people who want to support the fight to preserve science funding at today’s #StandUpForScience in SF @standupforscience.bsky.social

Amazing turnout at today’s #StandUpForScience in San Francisco